skip to content
Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.). Preview this item
ClosePreview this item
Checking...

Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).

Author: Canadian Agency for Drugs and Technologies in Health,
Publisher: Ottawa (ON) : Canadian Agency for Drugs and Technologies in Health, December 2017.
Series: Common drug review clinical review report.
Edition/Format:   eBook : Document : English
Summary:
Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL  Read more...
Rating:

(not yet rated) 0 with reviews - Be the first.

Subjects
More like this

Find a copy online

Links to this item

Find a copy in the library

&AllPage.SpinnerRetrieving; Finding libraries that hold this item...

Details

Material Type: Document, Internet resource
Document Type: Internet Resource, Computer File
All Authors / Contributors: Canadian Agency for Drugs and Technologies in Health,
OCLC Number: 1085636660
Description: 1 online resource (1 PDF file (28 pages)) : illustrations.
Series Title: Common drug review clinical review report.
Other Titles: Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)
Pharmacoeconomic review report for Adlyxine

Abstract:

Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL and 0.1 mg/mL, delivering 14 doses of 10 mcg per dose or 20 mcg per dose. The submitted price of lixisenatide is $56.98 per injector pen (regardless of strength) or $1,486 annually.

Reviews

User-contributed reviews
Retrieving GoodReads reviews...
Retrieving DOGObooks reviews...

Tags

Be the first.
Confirm this request

You may have already requested this item. Please select Ok if you would like to proceed with this request anyway.

Linked Data


Primary Entity

<http://www.worldcat.org/oclc/1085636660> # Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).
    a schema:CreativeWork, schema:MediaObject, schema:Book ;
    library:oclcnum "1085636660" ;
    library:placeOfPublication <http://id.loc.gov/vocabulary/countries/onc> ;
    schema:about <http://experiment.worldcat.org/entity/work/data/8925247850#Topic/hypoglycemic_agents_economics> ; # Hypoglycemic Agents--economics
    schema:about <http://experiment.worldcat.org/entity/work/data/8925247850#Place/canada> ; # Canada.
    schema:about <http://experiment.worldcat.org/entity/work/data/8925247850#Topic/glucagon_like_peptide_1_receptor_agonists> ; # Glucagon-Like Peptide-1 Receptor--agonists
    schema:about <http://experiment.worldcat.org/entity/work/data/8925247850#Topic/diabetes_mellitus_type_2_drug_therapy> ; # Diabetes Mellitus, Type 2--drug therapy
    schema:about <http://experiment.worldcat.org/entity/work/data/8925247850#Topic/cost_benefit_analysis> ; # Cost-Benefit Analysis
    schema:alternateName "Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)" ;
    schema:alternateName "Pharmacoeconomic review report for Adlyxine" ;
    schema:bookFormat schema:EBook ;
    schema:contributor <http://experiment.worldcat.org/entity/work/data/8925247850#Organization/canadian_agency_for_drugs_and_technologies_in_health> ; # Canadian Agency for Drugs and Technologies in Health,
    schema:datePublished "2017" ;
    schema:description "Lixisenatide (Adlyxine) is a glucagon-like peptide-1 receptor agonist indicated for the treatment of type 2 diabetes mellitus in patients uncontrolled on basal insulin with or without oral glucose-lowering agents. The starting dose is 10 mcg once daily for 14 days, then increased to 20 mcg once daily. It is supplied as a solution in a pre-filled injector pen for subcutaneous administration in strengths of 0.05 mg/mL and 0.1 mg/mL, delivering 14 doses of 10 mcg per dose or 20 mcg per dose. The submitted price of lixisenatide is $56.98 per injector pen (regardless of strength) or $1,486 annually."@en ;
    schema:exampleOfWork <http://worldcat.org/entity/work/id/8925247850> ;
    schema:inLanguage "en" ;
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8925247850#Series/cadth_common_drug_review> ; # CADTH common drug review
    schema:isPartOf <http://experiment.worldcat.org/entity/work/data/8925247850#Series/common_drug_review_clinical_review_report> ; # Common drug review clinical review report.
    schema:name "Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.)."@en ;
    schema:productID "1085636660" ;
    schema:url <http://www.ncbi.nlm.nih.gov/books/NBK534150/> ;
    wdrs:describedby <http://www.worldcat.org/title/-/oclc/1085636660> ;
    .


Related Entities

<http://experiment.worldcat.org/entity/work/data/8925247850#Organization/canadian_agency_for_drugs_and_technologies_in_health> # Canadian Agency for Drugs and Technologies in Health,
    a schema:Organization ;
    schema:name "Canadian Agency for Drugs and Technologies in Health," ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Series/cadth_common_drug_review> # CADTH common drug review
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1085636660> ; # Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).
    schema:name "CADTH common drug review" ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Series/common_drug_review_clinical_review_report> # Common drug review clinical review report.
    a bgn:PublicationSeries ;
    schema:hasPart <http://www.worldcat.org/oclc/1085636660> ; # Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).
    schema:name "Common drug review clinical review report." ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Topic/cost_benefit_analysis> # Cost-Benefit Analysis
    a schema:Intangible ;
    schema:name "Cost-Benefit Analysis"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Topic/diabetes_mellitus_type_2_drug_therapy> # Diabetes Mellitus, Type 2--drug therapy
    a schema:Intangible ;
    schema:name "Diabetes Mellitus, Type 2--drug therapy"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Topic/glucagon_like_peptide_1_receptor_agonists> # Glucagon-Like Peptide-1 Receptor--agonists
    a schema:Intangible ;
    schema:name "Glucagon-Like Peptide-1 Receptor--agonists"@en ;
    .

<http://experiment.worldcat.org/entity/work/data/8925247850#Topic/hypoglycemic_agents_economics> # Hypoglycemic Agents--economics
    a schema:Intangible ;
    schema:name "Hypoglycemic Agents--economics"@en ;
    .

<http://www.worldcat.org/title/-/oclc/1085636660>
    a genont:InformationResource, genont:ContentTypeGenericResource ;
    schema:about <http://www.worldcat.org/oclc/1085636660> ; # Pharmacoeconomic review report. Lixisenatide (Adlyxine) (Sanofi-aventis Canada Inc.).
    schema:dateModified "2019-02-15" ;
    void:inDataset <http://purl.oclc.org/dataset/WorldCat> ;
    .


Content-negotiable representations

Close Window

Please sign in to WorldCat 

Don't have an account? You can easily create a free account.